Creating Vaccines & Therapeutics Against Global Health Challenges
VaxSyna utilizes a easily modifiable Vaccine Platform to address unmet needs for both established and emerging infectious diseases
Naturally forming complexes
Platform Monomer
The vaccine platform displays multiple antigens on self-assembling higher order antibody complexes to induce a pathogen-specific immune response in minimal doses without an adjuvant
Multiple Antigen Display
Full Protection in 1-2 Doses
Easy to Modify
Our patented vaccine platform is made up of a human IgG antibody fused to a target vaccine antigen and an epitope tag specific to the vaccine platform's antibody. This configuration enables higher-order antibody complexes that trigger the immune response through Fc-Receptor binding and crosslinking. The platform is easily modified to any size target antigen and multiple antigens can be displayed on either the C- or N- terminus of the platform IgG.
Members of and Working with:
Krea Medica
Publications and Patents
Diamos AG, Pardhe MD, Bergeman MH, Kamzina AS, DiPalma MP, Aman S, et al. A self-binding immune complex vaccine elicits strong neutralizing responses against herpes simplex virus in mice. Front Immunol 2023;14:1085911. https://doi.org/10.3389/fimmu.2023.1085911.
Diamos AG, Pardhe MD, Sun H, Hunter JGL, Mor T, Meador L, et al. Codelivery of improved immune complex and virus-like particle vaccines containing Zika virus envelope domain III synergistically enhances immunogenicity. Vaccine 2020;38:3455–63. https://doi.org/10.1016/j.vaccine.2020.02.089.
Diamos AG, Pardhe MD, Sun H, Hunter JGL, Kilbourne J, Chen Q, et al. A Highly Expressing, Soluble, and Stable Plant-Made IgG Fusion Vaccine Strategy Enhances Antigen Immunogenicity in Mice Without Adjuvant. Front Immunol 2020;11:576012. https://doi.org/10.3389/fimmu.2020.576012.
Diamos AG, Larios D, Brown L, Kilbourne J, Kim HS, Saxena D, et al. Vaccine synergy with virus-like particle and immune complex platforms for delivery of human papillomavirus L2 antigen. Vaccine 2019;37:137–44. https://doi.org/10.1016/j.vaccine.2018.11.021.
Diamos AG, Mason HS. High-level expression and enrichment of norovirus virus-like particles in plants using modified geminiviral vectors. Protein Expres Purif 2018;151:86–92. https://doi.org/10.1016/j.pep.2018.06.011.
Mason, H. S., Diamos, A. G., & Pushko, P. (2021). Universal vaccine platform comprising virus-like particles and recombinant immune complexes (U.S. Pub. No. US 2021/0330785 A1). U.S. Patent and Trademark Office.
Mason HS. Recombinant immune complexes as versatile and potent vaccines. Hum Vacc Immunother 2016;12:988–9. https://doi.org/10.1080/21645515.2015.1116655.